Roy and Diana Vagelos Division of Biology and Biomedical Sciences, Washington University School of Medicine, St. Louis, MO 63110, United States.
Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, MO 63110, United States.
Stem Cells Transl Med. 2024 Oct 10;13(10):949-958. doi: 10.1093/stcltm/szae059.
Stem cell-derived islets (SC-islets) offer the potential to be an unlimited source of cells for disease modeling and the treatment of diabetes. SC-islets can be genetically modified, treated with chemical compounds, or differentiated from patient derived stem cells to model diabetes. These models provide insights into disease pathogenesis and vulnerabilities that may be targeted to provide treatment. SC-islets themselves are also being investigated as a cell therapy for diabetes. However, the transplantation process is imperfect; side effects from immunosuppressant use have reduced SC-islet therapeutic potential. Alternative methods to this include encapsulation, use of immunomodulating molecules, and genetic modification of SC-islets. This review covers recent advances using SC-islets to understand different diabetes pathologies and as a cell therapy.
干细胞衍生的胰岛 (SC-islets) 为疾病建模和糖尿病治疗提供了成为无限细胞来源的潜力。SC-islets 可以进行基因修饰、用化合物处理或从患者来源的干细胞分化,以模拟糖尿病。这些模型提供了对疾病发病机制和脆弱性的深入了解,这些脆弱性可能成为治疗的目标。SC-islets 本身也被作为糖尿病的细胞疗法进行研究。然而,移植过程并不完美;免疫抑制剂使用的副作用降低了 SC-islets 的治疗潜力。替代方法包括封装、使用免疫调节分子和 SC-islets 的基因修饰。本综述涵盖了使用 SC-islets 来理解不同糖尿病病理和作为细胞疗法的最新进展。